TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - TG Therapeutics, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025, with a fireside chat on September 8 at 10:30am ET [1] Company Overview - TG Therapeutics is a fully integrated, commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases [3] - The company has received FDA approval for BRIUMVI (ublituximab-xiiy) for treating adult patients with relapsing forms of multiple sclerosis, and it has also received approvals from regulatory agencies in Europe, the UK, Switzerland, and Australia for the same treatment [3]